News | June 11, 2010

Heart Attacks Declined Significantly in Northern California Since 2000

June 11, 2010 – Heart attacks declined by 24 percent within a large, ethnically diverse, community-based population since 2000. The relative incidence of serious heart attacks that do permanent damage also declined 62 percent, according to a Kaiser Permanente Division of Research study in the current issue of the New England Journal of Medicine.

The reductions in death after heart attack are driven in part by the decline in incidence of more severe heart attacks known as ST-elevation myocardial infarction (STEMI), as well as a lower mortality rate after less severe non-ST-elevation heart attacks, explained Alan S. Go, M.D., the lead investigator of the study and director of the comprehensive clinical research unit at the Kaiser Permanente Division of Research in Oakland, Calif.

This study of more than 46,000 patients in Northern California aged 30 years and older who suffered a heart attack is the first study to provide a contemporary population view of heart attack incidence in a large, diverse community. Previous studies focused on selected subgroups and/or populations with limited diversity and have not separately examined ST-elevation and non-ST-elevation heart attacks. It is also the first to examine the possible influence of widespread use of cardiac biomarkers (particularly troponin) on heart attack trends, which may lead to an increase in the reported rate of heart attacks, particularly non-ST-elevation heart attacks.

"This research provides new insights into the changing landscape of heart attack incidence and associated outcomes in the community," Go said. "Despite our ability to more easily diagnosis heart attacks using sensitive biomarkers, we found a consistent trend of fewer severe ST-elevation myocardial infarctions over the past decade — the type of heart attack we particularly want to prevent."

Heart attacks with ST-elevation are a true emergency, most often requiring an immediate procedure to open the blocked artery, noted Robert W. Yeh, M.D., an interventional cardiologist at the Massachusetts General Hospital and Harvard Medical School who was the first-author of the study. "These findings are welcome news for those of us in the cardiology community. Perhaps we have turned the corner on preventing the most severe presentation of heart disease."

Researchers identified 46,086 patients aged 30 and older within Kaiser Permanente in Northern California who were hospitalized for heart attacks between 1999-2008. They found the age- and sex-adjusted incidence of heart attack increased from 274 per 100,000 in 1999 to 287 per 100,000 in 2000, then declined each year thereafter to 208 per 100,000 in 2008 (24 percent decline between 1999 and 2008). However, the age- and sex-adjusted incidence of ST-elevation myocardial infarction declined by 62 percent from 133 per 100,000 in 1999 to 50 per 100,000 in 2008. Age- and sex-adjusted incidence of non-ST-elevation myocardial infarction also declined since 2005, which followed widespread implementation of sensitive cardiac testing known as troponin I, which helps diagnose heart attacks. Thirty-day mortality was significantly lower in 2008 compared to 1999.

Because the study population is within an integrated delivery system, it provided an accurate assessment of total membership at any point in time and comprehensive identification of those hospitalized for heart attack. The population has broad age, gender, and ethnic diversity and is highly representative of the local and statewide population. Researchers also demonstrated that the results were consistent after removing the possible effects of different types of patients joining or leaving the health plan membership over time.

Additional authors on the study are Stephen Sidney, M.D., MPH; Malini Chandra, MBA, MS; Mike Sorel, MPH and Joe V. Selby, M.D., MPH, with the Kaiser Permanente Division of Research. Funding for the study was provided by the Schering-Plough Future Leaders in Cardiovascular Medical Research Grant and The Permanente Medical Group, whose 7,000 physicians provide care for 3.3 million Kaiser Permanente members in Northern California.

For more information: www.dor.kaiser.org, www.massgeneral.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init